Article: PURE Bioscience Announces the Cleveland Clinic Has Taken an Equity Stake in FTA Therapeutics.

FTA Therapeutics, PURE's Pharmaceutical Development Partner, Names Board of Directors

SAN DIEGO -- PURE Bioscience (NASDAQ: PURE) today announced that Cleveland Clinic has been issued an equity stake in FTA Therapeutics LLC, PURE's pharmaceutical development partner for its patented silver dihydrogen citrate (SDC) antimicrobial.

Dr. Frank Papay, co-founder of FTA, commented, "After a lengthy and thorough evaluation process, we are proud to announce that one of the top hospitals in the world, Cleveland Clinic which has one of the largest biomedical engineering department in the US, has agreed to work with FTA as part of FTA's development projects with ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!